Non‑synonymous polymorphisms in the HRC and ADRB1 genes may be associated with all‑cause death in patients with non‑ischemic heart failure
Tanise Machado Telles1, Bruna Miers May2, Mauricio Pimentel2
1Laboratory of Human Molecular Genetics, Lutheran University of Brazil, Canoas, Rio Grande do Sul 92425-900, Brazil.
Insights
Genetic variants in calcium signaling genes, specifically the histidine-rich calcium-binding protein (HRC) Ser96Ala polymorphism, are linked to worse survival in heart failure patients. This finding may improve risk stratification for sudden cardiac death and implantable cardioverter-defibrillator (ICD) selection.
Area of Science:
- Cardiology
- Genetics
- Molecular Biology
Background:
- Sudden cardiac death (SCD) is a major concern in heart failure (HF) patients, often linked to arrhythmias caused by calcium handling alterations.
- Genetic variations in calcium signaling pathways are associated with SCD risk.
Purpose of the Study:
- To investigate the association of specific gene polymorphisms (HRC Ser96Ala, ADRB1 Ser49Gly, ADRB1 Arg389Gly, RYR2 Gly1886Ser) with serious arrhythmic events and mortality in non-ischemic HF patients with reduced ejection fraction.
Main Methods:
- Retrospective cohort study of 136 HF patients.
- Invasive electrophysiological study, physical examination, laboratory tests, and cardiac function assessment.
- Follow-up for serious arrhythmic events (SCD or appropriate ICD therapy) and all-cause death.
Main Results:
- The histidine-rich calcium-binding protein (HRC) Ser96Ala polymorphism's Ser allele was associated with poorer survival (log-rank P=0.043).
- Beta-1 adrenergic receptor (ADRB1) Ser49Ser/Arg389Arg genotypes showed a trend towards increased mortality risk, but this was not statistically significant after covariate adjustment.
- No association was found for the ryanodine receptor 2 (RYR2) Gly1886Ser polymorphism.
Conclusions:
- The HRC Ser96Ala polymorphism may serve as a prognostic marker in HF patients, potentially aiding in risk stratification and guiding decisions for implantable cardioverter-defibrillator (ICD) implantation.
- ADRB1 and RYR2 polymorphisms showed no significant association with outcomes in this cohort.
Abstract:
Sudden cardiac death (SCD) is an unpredictable and common mode of death in patients with heart failure (HF). Alterations in calcium handling may lead to malignant arrhythmias, resulting in SCD, and variants in calcium signaling-related genes have a significant association with SCD. Therefore, the aim of the present retrospective cohort study was to investigate the association of Ser96Ala [histidine-rich calcium-binding protein (HRC)], Ser49Gly [β1-adrenergic receptor (ADRB1)], Arg389Gly (ADRB1) and Gly1886Ser [ryanodine receptor 2 (RYR2)] polymorphisms with serious arrhythmic events and overall mortality in patients with HF with reduced left ventricular ejection fraction of non-ischemic etiology. In total, 136 patients with HF underwent physical examination, routine laboratory tests, non-invasive assessment of cardiac function and an invasive electrophysiological study. The primary outcome was the occurrence of serious arrhythmic events, set as either SCD or appropriate implantable cardioverter-defibrillator (ICD) therapy, and the secondary outcome was all-cause death. During a median follow-up of 37 months, arrhythmic events occurred in 26 patients (19%) and 41 patients (30%) died. Patients carrying the Ser allele of the Ser96Ala polymorphism in HRC had worse survival than those with the Ala/Ala genotype (log-rank P=0.043). Despite the difference in survival time, the Ala/Ala genotype was not associated with all-cause death in the regression analysis [unadjusted hazard ratio (HR)=0.17; 95% CI, 0.02-1.21]. Regarding the Ser49Gly and Arg389Gly polymorphisms in ADRB1, homozygosity for the major alleles at both sites (Ser49Ser and Arg389Arg) was associated with a two-fold increased risk of all-cause death compared with the other genotype combinations (unadjusted HR=1.98; 95% CI, 1.02-3.82). However, this association was lost after controlling for clinical covariates. No association was observed for the Gly1886Ser polymorphism in RYR2. Overall, the present findings are concurrent with the hypothesis that the Ser96Ala (HRC), Ser49Gly (ADRB1) and Arg389Gly (ADRB1) polymorphisms may be associated with HF prognosis. In particular, the Ser96Ala polymorphism might aid in risk stratification and patient selection for ICD implantation.
More Related Videos
09:34Targeted Next-generation Sequencing and Bioinformatics Pipeline to Evaluate Genetic Determinants of Constitutional Disease
Published on: April 4, 2018
09:37A Phenotyping Regimen for Genetically Modified Mice Used to Study Genes Implicated in Human Diseases of Aging
Published on: July 14, 2016
Related Concept Videos
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
Hazard Ratio
For example, in a clinical trial...
Pathophysiology of Heart Failure
Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
Genome-wide Association Studies-GWAS
GWAS does not require the identification of the target gene involved in...
Heart Failure Drugs: β-Blockers
